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Aim of database: The Danish Prostate Cancer Database (DAPROCAdata) is a nationwide 
clinical cancer database that has prospectively collected data on patients with incident prostate 
cancer in Denmark since February 2010. The overall aim of the DAPROCAdata is to improve 
the quality of prostate cancer care in Denmark by systematically collecting key clinical variables 
for the purposes of health care monitoring, quality improvement, and research.
Study population: All Danish patients with histologically verified prostate cancer are included 
in the DAPROCAdata.
Main variables: The DAPROCAdata registers clinical data and selected characteristics for 
patients with prostate cancer at diagnosis. Data are collected from the linkage of nationwide 
health registries and supplemented with online registration of key clinical variables by treating 
physicians at urological and oncological departments. Main variables include Gleason scores, 
cancer staging, prostate-specific antigen values, and therapeutic measures (active surveillance, 
surgery, radiotherapy, endocrine therapy, and chemotherapy).
Descriptive data: In total, 22,332 patients with prostate cancer were registered in 
 DAPROCAdata as of April 2015. A key feature of DAPROCAdata is the routine collection 
of patient-reported outcome measures (PROM), including data on quality-of-life (pain levels, 
physical activity, sexual function, depression, urine and fecal incontinence) and lifestyle factors 
(smoking, alcohol consumption, and body mass index). PROM data are derived from question-
naires distributed at diagnosis and at 1-year and 3-year follow-up. Hitherto, the PROM data have 
been limited by low completeness (26% among newly diagnosed patients in 2014).
Conclusion: DAPROCAdata is a comprehensive, yet still young clinical database. Efforts to 
improve data collection, data validity, and completeness are ongoing and of high priority.
Keywords: prostate cancer, clinical quality indicators, database research
Introduction
The Danish Prostate Cancer Database (DAPROCAdata) is a nationwide clinical can-
cer database that prospectively collects data on key clinical parameters for prostate 
cancer (Table 1). DAPROCAdata is closely affiliated with the national expert group, 
the Danish Prostate Cancer Group (DAPROCA), which consists of clinicians and 
scientists responsible for developing and maintaining national clinical guidelines for 
the treatment of prostate cancer in Denmark.1
Aim of database
The overall aim of DAPROCAdata and the DAPROCA expert group is to improve the 
quality of care and management of patients with prostate cancer in Denmark. More 
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specifically, the purpose of DAPROCAdata is to systemati-
cally collect key clinical parameters on all patients with inci-
dent prostate cancer in Denmark for health care monitoring, 
quality improvement, and research.
Study population
DAPROCAdata has collected data on all incident, histologi-
cally verified prostate cancer cases in Denmark since  February 
2010 and as of April 2015, a total of 22,332 patients were 
registered in the database (Table 2). The inclusion criteria are 
registration in the Danish Pathology Registry2 with either: 
1) SNOMED codes T77x (prostate and seminal vesicles) and 
M8xxx3 (all malignant invasive neoplasms in the prostate) or 
2) SNOMED codes ÆF4620 (metastases originating from the 
prostate). The exclusion criteria are: 1) inconclusive prostate 
cancer diagnosis (eg, a relevant M-code registered together 
with the diagnosis code ÆYYY00, “obs. pro”); 2) patients 
with temporary personal identification numbers (ie, non-
permanent residents); and 3) patients diagnosed in relation 
to having undergone cystectomy (surgical codes: KKCC10, 
KKCC11, KKCC20, KKCC21).
Main variables
Clinical data and selected characteristics for patients with 
prostate cancer at the time of diagnosis are systematically 
recorded in DAPROCAdata by a combination of automatized 
linkage to nationwide health registries (eg, the Danish Patho-
logy Registry, the Danish National Patient Register,3 and the 
Civil Registration System4) and online registration of key 
clinical parameters by treating clinicians at the surgical and 
oncological departments.
Diagnostic and tumor characteristics are retrieved from 
the Danish Pathology Registry (eg, histological verification, 
Gleason score, and TNM staging). Supplementary data are 
obtained from the Danish National Patient Register (eg, medi-
cal history and previous surgical procedures prior to prostate 
cancer). Data on vital status and migration are obtained from 
the Civil Registration System.4 Furthermore, an ongoing 
medical record validation study evaluates the feasibility 
of including data on cause-specific death from the Danish 
Table 1 Overview of the DAPROCAdata
General information
Patient  
population
incident prostate  
cancer
Data collection since  
February 2010
Data coverage Nationwide 22 urological and oncological 
departments participating in  
data registration
Data collection Continuous Data linkage from central  
registries combined with  
online prospective data  
collection of key clinical  
variables by treating clinicians
Clinical quality 
indicators
N=10
Clinical data 
registration forms
Diagnosis Clinical Data Registration Form
Urology Clinical Data Registration Form
Oncology Clinical Data Registration Form
PROM questionnaires Data collection since May 2011
At diagnosis
1-year follow-up
3-year follow-up
Treatment variables Oncology
Surgery
Radiation therapy
endocrine treatment
Pathology variables Gleason score 
TNM stage
Laboratory variable PSA at diagnosis
Comorbidity  
variablesa
CCi
0= none
1= low
2= medium
3= high
Administrative  
variables
Region
Hospital site
Department
Note: aCCi scores are systematically added to DAPROCAdata during conversion 
to the DNKK.
Abbreviations: CCi, Charlson Comorbidity index; DAPROCAdata, Danish 
Prostate Cancer Database; DNKK, Danish National Cancer Clinical Database; 
PROM, patient-reported outcome measures; PSA, prostate-specific antigen; TNM, 
tumor, node, and metastasis cancer stage classification.
Table 2 Summary of patient population (patients diagnosed 
in the period from 2010 to April 2015) in DAPROCAdata by 
treatment group
Treatment groups Number (N)a
Total number of patients with  
prostate cancer registered in 
DAPROCAdata
N=22,332 (2010 to April 2015)
N=4,077 (2010)
N=4,229 (2011)
N=4,279 (2012)
N=4,252 (2013)
N=4,581 (2014)
N=914 (January 2015 to April 2015)
Patients with prostatectomy N=4,795
Patients with radiotherapy N=6,118 (total)
 Curative intent N=3,324
 Palliative intent N=2,794
Patients with endocrine therapy N=7,628
Patients with registered history of 
chemotherapy
N=508
Patients registered with active 
surveillance (based on the 
DAPROCA Urology Clinical Data 
Registration Form)
N=2,327
Note: aData (as of April 2015) from the DAPROCAdata 2014 Annual Report.6
Abbreviations: DAPROCAdata, Danish Prostate Cancer Database; DAPROCA, 
Danish Prostate Cancer Group.
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Table 3 Clinical quality indicators in DAPROCAdata (year 2014)
Indicator Description of indicator Type of 
indicator
Standarda
indicator 1: hospital admission after  
TRUS
Proportion of patients admitted after TRUS-guided biopsy Process ,5%
indicator 2a: active surveillance after  
1 year
Proportion of patients under “active surveillance” without events  
after 1 year
Process .70%
indicator 2b: active surveillance after  
3 years
Proportion of patients under “active surveillance” without events  
after 3 years
Process .50%
indicator 3: positive surgical  
margin (pT2)
Proportion of RP patients (pT2) with positive surgical margins Result ,25%
indicator 4: positive surgical  
margin (pT3)
Proportion of RP patients (pT3) with positive surgical margins Result ,40%
indicator 5: postoperative morbidity Proportion of patients with postoperative admission .3 days Result ,5%
indicator 6: 30-day morbidity Proportion of patients readmitted with complications ,30 days  
after RP operation
Result ,5%
indicator 7a: 1-year morbidity Proportion of RP patients with any hospital admission .30 days  
and ,1 year after operation
Result Not 
defined
indicator 7b: 1-year morbidity Proportion of RP patients with any hospital admission .30 days  
and ,1 year after radiation therapy
Result Not 
defined
indicator 8: 1-year mortality Proportion of RP patients deceased ,1 year after operation Result ,1%
indicator 9a: endocrine treatment  
for T1/T2
Proportion of patients with T1/T2 disease (,T3; No/Nx;  
Mo/Mx; PSA,40) receiving endocrine treatment ,6 months  
after diagnosis (M+)
Process ,25%
indicator 9b: endocrine treatment  
for N1
Proportion of patients with N1 stage (N1; Mo/Mx/Missing M)  
receiving endocrine treatment ,6 months after diagnosis
Process .75%
indicator 9c: endocrine treatment  
for M1
Proportion of patients with metastases (M1) receiving endocrine 
treatment ,6 months after diagnosis (,T3No; Nx; Mo; Mx;  
PSA ,40)
Process .75%
indicator 10a: data completeness Proportion of diagnosed patients with PSA, cardinal symptoms,  
and cTNM variables registered in the DAPROCA – Diagnosis  
Clinical Data Registration Form
Result .90%
indicator 10b: data completeness Proportion of RP patients with registration of treatment history  
in the DAPROCA – Urology Clinical Data Registration Form
Result .80%
indicator 10c: Data completeness Proportion of patients receiving curative radiotherapy and with 
a registration of the date of clinical decision making in the  
DAPROCA – Oncology Clinical Data Registration Form
Result .90%
indicator 10d: data completeness Proportion of patients with completed PROM questionnaires Result .80%
Note: aStandard =% fulfillment of indicator.
Abbreviations: DAPROCAdata, Danish Prostate Cancer Database; DAPROCA, Danish Prostate Cancer Group; PROM, patient-reported outcome measures; PSA, 
prostate-specific antigen; RP, radical prostatectomy; TRUS, transrectal ultrasound; TNM, tumor, node, and metastasis cancer stage classification.
Causes of Death Registry5 in DAPROCAdata. Key data 
related to the index prostate cancer diagnosis are registered by 
physicians at the treating urological and oncological centers 
using a specifically developed online registration system. 
These data include prostate-specific antigen values, prostate 
cancer-related surgical procedures, and oncological therapy. 
Separate data registration forms are used for the collection of 
data at the time of diagnosis and for subsequent urological 
and oncological information.
A key feature of DAPROCAdata is the routine collec-
tion of patient-reported outcome measures (PROM) since 
2011. Patient questionnaires recording adverse effects 
following treatment and general quality-of-life aspects are 
collected at diagnosis, and at 1-year and 3-year follow-up. 
In 2014, the completeness of PROM questionnaire data 
from all newly diagnosed patients was only 26%; however, 
the response proportion at 1-year follow-up among those 
selected to participate in the initial survey was high (92%).6 
In addition to quality-of-life measurements (eg, pain levels, 
physical activity, sexual function, depression, urine and fecal 
incontinence), the PROM questionnaires also collect data on 
lifestyle factors such as smoking, alcohol consumption, and 
body mass index.
In 2014, the completeness of online clinical registrations 
reached 70%.6 In addition, in 2014, ten clinical quality indica-
tors were defined by the DAPROCAdata Steering Committee 
with the aim of improving quality assessment related to the 
diagnosis, treatment, and recurrence of prostate cancer in 
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Denmark. The DAPROCAdata Steering Committee regularly 
evaluates the clinical relevance and utility of the clinical 
quality indicators in an ongoing effort toward continued 
refinement and quality improvement. Table 3 summarizes the 
clinical quality indicators and standards defined in 2014.
Follow-up
DAPROCAdata has complete follow-up on all registered 
patients with prostate cancer. All patients are followed 
from the date of inclusion in  DAPROCAdata (ie, the date 
of cancer diagnosis) until death or emigration. This is 
possible by means of automatized linkage to the Danish 
Civil Registration System for information on vital status 
and residency.
Examples of research
Since its establishment in 2010, DAPROCAdata has created 
the basis for annual quality improvement reports with detailed 
analyses of the clinical quality indicators.6 As the clinical 
database is young, the data presented in the existing annual 
reports should be interpreted with caution and especially 
reports from the very first years after establishment. Data 
completeness was low during the first year and not all relevant 
clinical departments participated in online data registration 
from the start. Nevertheless, the annual reports for the first 
5 years document that data validity and completeness have 
steadily improved, as has the performance of the clinical qual-
ity indicators against the predefined set of quality indicator 
standards (Table 3).
Several validation and epidemiological studies based on 
data from the initial 5 years of follow-up from 2010 to 2014 
are in progress (data not published). DAPROCAdata will also 
participate in the DMCG.dk Benchmarking Consortium7 with 
planned benchmarking analyses on survival and mortality.
Administration and funding
DAPROCAdata is under the auspices of the Danish Multi-
disciplinary Cancer Groups (DMCG.dk), which is an 
umbrella organization comprised of 24 national, disease-
specific cancer groups and clinical databases.8 The urological 
cancer groups and databases are further organized under the 
 Danish  Urological Cancer Group.9 DAPROCAdata is funded 
by the Danish Regions10 and is administered by the Danish 
Clinical Registries (RKKP).11 Technical support and data 
management is provided by the Registry Support Centre 
for Clinical  Quality and Health Informatics (KCKS-Vest).12 
Epidemiological and statistical support in the preparation of 
annual reports is provided by the Registry Support Centre 
for Epidemiology and Biostatistics, North (KCEB-Nord).13 
The nationwide collection of PROM data at all urologic and 
oncologic  centers in Denmark is performed in collaboration 
with WestChronic.14,15 In 2015, the Danish Cancer Society 
collaborated with DAPROCA and WestChronic in a 1-year 
parallel project on PROM data from prostate cancer patients, 
but restricted to five participating centers.
The DAPROCAdata Steering Committee is comprised 
of clinicians and academic experts representing urology, 
oncology, pathology, epidemiology, biostatistics, and quality 
improvement science. In addition to ongoing refinement of 
the clinical quality indicators and the publication of annual 
reports, the Steering Committee promotes initiatives to 
improve data completeness, validity, and coding practices.
Data are collected in accordance with current Danish data 
protection laws (Sundhedslovens § 196, stk 4 – law nr 546, 
dated June 24, 2005/law nr 603, dated June 18, 2012). Laws 
and procedures for data access to DAPROCAdata are gov-
erned by the Data Protection Agency (Datatilsynet) and the 
National Board of Health (Sundhedsstyrelsen). Applications 
for access to DAPROCAdata are reviewed by the Chair and 
Steering Committee following application to RKKP.
Conclusion
DAPROCAdata was established in 2010 and is, thus, 
a relatively young clinical database. Efforts to improve 
data collection, data validity, and data completeness are 
ongoing and of high priority. Updated information on DAP-
ROCAdata is available at DAPROCA’s internet homepage: 
http://ducg.dk/daproca-prostatacancer/.
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